QIAGEN (QGEN)
(Delayed Data from NYSE)
$46.05 USD
+0.12 (0.26%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $46.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.05 USD
+0.12 (0.26%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $46.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Zacks News
4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis
by Debanjana Dey
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
3 Medical Stocks Poised to Trounce Market on Coronavirus Scare
by Urmimala Biswas
Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.
Is QIAGEN N.V. (QGEN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening
by Zacks Equity Research
BD (BDX) expects screening to ramp up by 1,000 per day once authorized.
QIAGEN's Coronavirus Test Kit Development Gets BARDA Funding
by Zacks Equity Research
QIAGEN (QGEN) receives support from the government to accelerate the development of the QIAstat-Dx test kit to detect the coronavirus causing virus.
BD MAX Gets CE Mark for Coronavirus Detection, Shares Up
by Zacks Equity Research
BD (BDX) and Spain's CerTest Biotec collaborate to detect the COVID-19 in Europe.
LabCorp (LH) Launches Test to Detect Presence of Coronavirus
by Zacks Equity Research
LabCorp (LH), with an aim to contain the outbreak of coronavirus, launches the LabCorp 2019 Novel Coronavirus (COVID-19), NAA test.
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
by Zacks Equity Research
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
3 MedTech Stocks to Rebound After Coronavirus-Led Recoil
by Sriparna Ghosal
As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Why Is Qiagen (QGEN) Up 19% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Mar 4, 2020
by Zacks Equity Research
Companies in the news are: SCON, OMER, QGEN, TLRY
Thermo Fisher (TMO) to Buy Molecular Diagnostics Major QIAGEN
by Zacks Equity Research
Thermo Fisher (TMO) expects QIAGEN's strong molecular diagnostics presence to complement its specialty diagnostics capabilities.
Will QIAGEN Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in QIAGEN.
Dropbox, Groupon, QIAGEN, Zoom Video Communications and Novavax highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Dropbox, Groupon, QIAGEN, Zoom Video Communications and Novavax highlighted as Zacks Bull and Bear of the Day
3 Stocks Are Gaining Even as Coronavirus Creates Chaos
by Sreyoshi Mukherjee
While key players in the United States are struggling to cope, the coronavirus has been a boon for some.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
QIAGEN Ships Test Kits to China for Detecting Coronavirus
by Zacks Equity Research
QIAGEN (QGEN) expands the molecular testing portfolio by shipping QIAstat-Dx Respiratory 2019-nCoV Panel to China for faster detection of coronavirus SARS-CoV-2.
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe
by Zacks Equity Research
QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4
Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 9.09% and 1.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. QGEN: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
by Zacks Equity Research
Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.